Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 406

1.

Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation.

Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, Antin JH, Alyea E, Armand P, Ho V, Koreth J, Neuberg D, Cutler CS, Ebert BL.

J Clin Oncol. 2014 Aug 4. pii: JCO.2013.52.3381. [Epub ahead of print]

PMID:
25092778
[PubMed - as supplied by publisher]
2.

Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.

Ceppi F, Langlois-Pelletier C, Gagné V, Rousseau J, Ciolino C, Lorenzo SD, Kevin KM, Cijov D, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Laverdière C, Krajinovic M.

Pharmacogenomics. 2014 Jun;15(8):1105-16. doi: 10.2217/pgs.14.68.

PMID:
25084203
[PubMed - in process]
3.

Long-term outcome of a pediatric-inspired regimen used for adults ages 18 to 50 with newly diagnosed acute lymphoblastic leukemia.

DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM.

Leukemia. 2014 Jul 31. doi: 10.1038/leu.2014.229. [Epub ahead of print]

PMID:
25079173
[PubMed - as supplied by publisher]
4.

De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.

Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C, Cascio MJ, Rogers HJ, Hsi ED, Soderquist C, Bagg A, Yan J, Ochs R, Orazi A, Moore F, Mahmoud A, George TI, Foucar K, Odem J, Booth C, Morice W, DeAngelo DJ, Steensma D, Stone RM, Neuberg D, Arber DA.

Am J Hematol. 2014 Jul 16. doi: 10.1002/ajh.23808. [Epub ahead of print]

PMID:
25042343
[PubMed - as supplied by publisher]
5.

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.

Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS.

Leuk Lymphoma. 2014 Aug 20:1-6. [Epub ahead of print]

PMID:
25012943
[PubMed - as supplied by publisher]
6.

Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.

Ben Tanfous M, Sharif-Askari B, Ceppi F, Laaribi H, Gagné V, Rousseau J, Labuda M, Silverman LB, Sallan SE, Neuberg D, Kutok JL, Sinnett D, Laverdière C, Krajinovic M.

Clin Cancer Res. 2014 Jun 6. pii: clincanres.0508.2014. [Epub ahead of print]

PMID:
24907114
[PubMed - as supplied by publisher]
7.

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.

Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, Cibulskis K, Sidney J, Stevenson K, Ritz J, Neuberg D, Brusic V, Gabriel S, Lander ES, Getz G, Hacohen N, Wu CJ.

Blood. 2014 Jul 17;124(3):453-62. doi: 10.1182/blood-2014-04-567933. Epub 2014 Jun 2.

PMID:
24891321
[PubMed - in process]
8.

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.

James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ.

J Clin Oncol. 2014 Jul 1;32(19):2067-73. doi: 10.1200/JCO.2013.51.5890. Epub 2014 May 27.

PMID:
24868031
[PubMed - indexed for MEDLINE]
9.

Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations.

Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM, Ramsay AG, Rassenti LZ, Kipps TJ, Gribben JG.

Blood. 2014 Jun 26;123(26):4101-10. doi: 10.1182/blood-2014-01-552307. Epub 2014 May 14.

PMID:
24829201
[PubMed - in process]
10.

Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study.

Zwicker JI, Rojan A, Campigotto F, Rehman N, Funches R, Connolly G, Webster J, Aggarwal A, Mobarek D, Faselis C, Neuberg D, Rickles FR, Wun T, Streiff MB, Khorana AA.

J Clin Oncol. 2014 Jun 10;32(17):1792-6. doi: 10.1200/JCO.2013.53.5336. Epub 2014 May 5.

PMID:
24799475
[PubMed - in process]
11.

Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis.

Brunner AM, Blonquist TM, Sadrzadeh H, Perry AM, Attar EC, Amrein PC, Ballen KK, Chen YB, Neuberg DS, Fathi AT.

Leuk Res. 2014 Jul;38(7):773-80. doi: 10.1016/j.leukres.2014.04.001. Epub 2014 Apr 12.

PMID:
24793731
[PubMed - indexed for MEDLINE]
12.

Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.

Wang L, Shalek AK, Lawrence M, Ding R, Gaublomme JT, Pochet N, Stojanov P, Sougnez C, Shukla SA, Stevenson KE, Zhang W, Wong J, Sievers QL, MacDonald BT, Vartanov AR, Goldstein NR, Neuberg D, He X, Lander E, Hacohen N, Regev A, Getz G, Brown JR, Park H, Wu CJ.

Blood. 2014 Aug 14;124(7):1089-98. doi: 10.1182/blood-2014-01-552067. Epub 2014 Apr 28.

PMID:
24778153
[PubMed - in process]
13.

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.

Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinge S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, te Kronnie G, Izraeli S, Harris MH, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JD, Pellman D, Weinstock DM.

Nat Genet. 2014 Jun;46(6):618-23. doi: 10.1038/ng.2949. Epub 2014 Apr 20.

PMID:
24747640
[PubMed - indexed for MEDLINE]
14.

Loss of function tp53 mutations do not accelerate the onset of myc-induced T-cell acute lymphoblastic leukaemia in the zebrafish.

Gutierrez A, Feng H, Stevenson K, Neuberg DS, Calzada O, Zhou Y, Langenau DM, Look AT.

Br J Haematol. 2014 Jul;166(1):84-90. doi: 10.1111/bjh.12851. Epub 2014 Apr 2.

PMID:
24690081
[PubMed - indexed for MEDLINE]
15.

An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.

Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC.

J Oncol Pharm Pract. 2014 Mar 24. [Epub ahead of print]

PMID:
24664476
[PubMed - as supplied by publisher]
16.

Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues.

Mutter GL, Monte NM, Neuberg D, Ferenczy A, Eng C.

Cancer Res. 2014 May 15;74(10):2796-802. doi: 10.1158/0008-5472.CAN-14-0108. Epub 2014 Mar 24. Erratum in: Cancer Res. 2014 Jul 1;74(13):3644.

PMID:
24662919
[PubMed - indexed for MEDLINE]
17.

Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.

Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, Neuberg DS, Sinha AU, Sallan SE, Silverman LB, Kung AL, Lo Nigro L, Ebert BL, Armstrong SA.

Nat Commun. 2014 Mar 24;5:3469. doi: 10.1038/ncomms4469.

PMID:
24662245
[PubMed - in process]
18.

Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.

Reynolds C, Roderick JE, Labelle JL, Bird G, Mathieu R, Bodaar K, Colon D, Pyati U, Stevenson KE, Qi J, Harris M, Silverman LB, Sallan SE, Bradner JE, Neuberg DS, Look AT, Walensky LD, Kelliher MA, Gutierrez A.

Leukemia. 2014 Feb 20. doi: 10.1038/leu.2014.78. [Epub ahead of print]

PMID:
24552990
[PubMed - as supplied by publisher]
19.

A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.

Deangelo DJ, Neuberg D, Amrein PC, Berchuck J, Wadleigh M, Sirulnik LA, Galinsky I, Golub T, Stegmaier K, Stone RM.

Leuk Res. 2014 Apr;38(4):430-4. doi: 10.1016/j.leukres.2013.10.026. Epub 2013 Nov 5.

PMID:
24522247
[PubMed - indexed for MEDLINE]
20.

Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution.

Dutcher JP, Neuberg D, Atkins MB, Tester WJ, Wadler S, Stewart JA, Chachoua A, Schuchter LM.

J Interferon Cytokine Res. 2014 May;34(5):376-84. doi: 10.1089/jir.2013.0010. Epub 2014 Jan 16.

PMID:
24433038
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk